Locations:
Search IconSearch
December 30, 2020/Cancer

Cleveland Clinic Surgeon Completes First Clinical Use of Newly Approved Ablation Device for Large Liver Tumors

The technology could reduce complications by offering patients an alternative to open liver surgeries

2015058_11-20-20_025_MK-Hero_650x450

Cleveland Clinic is the first hospital in the world to use a recently FDA-approved ablation technology that can destroy large liver tumors. The new device from Medtronic is called the Emprint™ HP Ablation System with Thermosphere™ Technology. The minimally invasive procedure uses a single needle connected to a powerful 150-watt microwave generator that can burn a malignant liver tumor as large as 2.4 inches (6 cm).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Eren Berber, MD, Director of Cleveland Clinic’s Surgical Liver Tumor Ablation Program, led a team that successfully used the device in October to treat a patient who had a 2.4-inch liver tumor. Following the minimally invasive procedure, the patient is doing well and postoperative imaging shows no trace of the tumor. Since the first case in October at Cleveland Clinic, Dr. Berber’s team has treated four more patients with large liver tumors using the technology.

“We’ve been using the previous versions of this technology,” says Dr. Berber. “But the challenge was that with a single needle, we were only able to create 4-centimeter burns. This technology is able to utilize 150 watts of power compared to the 100 watts that we used before. We’re also now able to create 6- or 7-centimeter burns with a single stick. This allowed us to treat larger tumors more confidently.”

Cleveland Clinic has been using ablation technologies to treat smaller tumors up to about 1.5 inches (4 cm) in diameter and not amenable to liver resection. Dr. Berber and his team have treated close to 1,000 patients with ablation and more than 200 patients with microwave ablation. It was because of this extensive experience with the technique and device that Dr. Berber was selected as the first clinical user. “This microwave ablation technology is very powerful, and if you don’t use it well, you can cause damage to the liver, you can cause bleeding or you can disrupt the tumor,” says Dr. Berber. “As the technology becomes more advanced and more powerful, gaining ablation expertise through experience becomes even more important.”

Understanding the procedure

To perform the procedure, a laparoscopic camera and an ultrasound probe are inserted in the abdomen through two small incisions. Then, a microwave needle is inserted through the skin into the liver tumor. When ready, the generator delivers heat to burn and destroy the lesion.

“Over the last six years, ablation technology evolved to incorporate microwave technology, which gives us a more homogeneous heating of the tissues by achieving higher temperatures,” explains Dr. Berber. “There is more balanced heating, and we can now reach higher tissue temperatures. Because of that, the success of ablation has greatly improved; the failure rate went down from 20% to 40% to about 10% or less.”

Identifying candidates

Dr. Berber notes that the best candidates for this procedure for treatment of large liver tumors are those with comorbidities which rendered them poor candidates for a major operation that would involve liver resection (cutting). This includes patients with multiple systemic diseases, heart problems, lung problems, or elderly patients who have decreased functional status who cannot tolerate a major operation. This procedure would be a good alternative for patients who would require surgery to remove a large portion of their liver. Open liver surgical procedures are associated with longer operative times and hospital stays, as well as higher incidence of complications.

Advertisement

“The goal is to offer the best treatment option for patients depending on their unique health condition,” says Dr. Berber In the hands of an experienced surgical team, the laparoscopic ablation technique benefits the patient, who experiences better postoperative recovery, less pain, a quicker return to normal life, and a lower risk of an incisional hernia compared with traditional open surgery.”

Dr. Berber has a consulting agreement with Medtronic and has received honoraria for consulting activities. He notes that his consulting agreements do not affect his choice of the best treatment option for his patients.

Advertisement

Related Articles

Dr. Holly Pederson
July 25, 2024/Cancer/Research
Evaluating Risk Scores for Triple-Negative Breast Cancer in Black Women (Podcast)

Polygenic risk score could help predict who will develop this aggressive breast cancer

Reviewing dental scans
July 8, 2024/Cancer
A Call for More Interdisciplinary and Preventive Care in New Osteoradionecrosis Guidelines

New guidelines offer insight into emerging therapies, dental issues and more

Dr. AlHilli
July 3, 2024/Cancer/Patient Support
Prehabilitation Program Aims to Improve Outcomes for Older Patients with Ovarian or Pancreatic Cancer

Clinical trial to assess the value of nutritional, physical therapy and social supports prior to preoperative chemotherapy

Dr. Nahleh
June 26, 2024/Cancer/Patient Support
Systemic Treatment a Major Factor Impacting Survival of Patients with Breast Cancer with Brain Metastasis

Research demonstrates improved overall survival for patients receiving comprehensive treatment for breast cancer in addition to radiation or surgical intervention for brain cancer

Image showing Dr. Gupta
June 20, 2024/Cancer/Research
Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

Ad